Latest Anemia News
No Reduction in Platelets Found With IV Iron Use in CKD
New study shows that IV iron repletion with sodium ferric gluconate complex increased platelet count significantly at week 3 post-infusion and non-significantly at week 4.
FDA Updates Triferic Label With New Safety Warning
Clinicians should advise women who could become pregnant to use effective contraception before and after taking the anemia drug.
Anticoagulation Therapy May Prevent CV Events, Worsen Anemia in CKD
In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.
Calcitriol Found Not to Improve Hepcidin Levels in CKD
In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.
Higher-Dose IV Iron Appears Safe in Dialysis
Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.
FDA Broadens Feraheme Use for Iron Deficiency Anemia
The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.
Most CKD Patients With Anemia Show Limited Response to Oral Iron
In a 52-week trial, more than half of nondialysis-dependent chronic kidney disease patients with anemia treated with oral iron had no rise in their hemoglobin levels.
Anemia in Dialysis Patients Linked With Hemorrhagic Stroke
Patients with hemoglobin values of 9.7 g/dL or below had more than double the risk for hemorrhagic stroke compared with patients with hemoglobin values of 11.2 g/dL or above.
CERA Effective for Pediatric Hemodialysis Patients With Anemia
The safety profile of CERA is similar for children as for adults.
Lower IV Iron Dosing in Anemic Dialysis Patients May Be More Effective
To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study.
Ceruloplasmin a Possible Marker of CKD in Sickle Cell Anemia
Urinary ceruloplamin has potential to be a chronic kidney disease biomarker for patients with sickle cell anemia.
Darbepoetin Alfa Safe for Pediatric CKD Patients With Anemia
Researchers tested once weekly and biweekly administration of darbepoetin alfa in children aged 1 to 18 years not previously treated with an erythropoiesis-stimulating agent.
Residual Renal Function Not Linked to ESA Requirements
Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.
Case: Treating Iron Deficiency Anemia in a Heart Failure Patient
To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.
High ESA and Iron Doses Up CVD, Death Risk in Hemodialysis Patients
High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.